COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • October 7th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Texas
This COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), is made as of September 29, 2008 by and between Repros Therapeutics Inc., a Delaware corporation, with its principal executive offices located at 2408 Timberloch Place, Suite B-7, The Woodlands, Texas 77380 (the “Company”), and Efficacy Capital, LTD (the “Investor”).
STANDSTILL AGREEMENTStandstill Agreement • March 18th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Delaware
This STANDSTILL AGREEMENT (the “Agreement”), dated as of January 9, 2008, is by and among REPROS THERAPEUTICS INC., a Delaware corporation (the “Issuer”), and EFFICACY CAPITAL, LTD (“Efficacy”).
FIRST AMENDMENT TO STANDSTILL AGREEMENTStandstill Agreement • October 7th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Delaware
This FIRST AMENDMENT TO STANDSTILL AGREEMENT (the “Amendment”), dated as of July , 2008, is by and between REPROS THERAPEUTICS INC., a Delaware corporation (the “Issuer”), and EFFICACY CAPITAL, LTD (“Efficacy”).
JOINT FILING AGREEMENTJoint Filing Agreement • March 18th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Repros Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of March 12, 2008.
JOINT FILING AGREEMENTJoint Filing Agreement • March 12th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13G (including amendments thereto) with regard to the common stock of Repros Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of December 31, 2006.
Initial Director’s Grant)Non-Employee Director’s Stock Option Agreement • October 7th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Delaware
AGREEMENT made as of the 26th day of September 2008, between REPROS THERAPEUTICS INC., a Delaware corporation (the “Company”), and Mark Lappe (“Director”).
SECOND AMENDMENT TO STANDSTILL AGREEMENTStandstill Agreement • October 7th, 2008 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances) • Delaware
This SECOND AMENDMENT TO STANDSTILL AGREEMENT (the “Amendment”), dated as of October 2, 2008, is by and between REPROS THERAPEUTICS INC., a Delaware corporation (the “Issuer”), and EFFICACY CAPITAL, LTD (“Efficacy”).
JOINT FILING AGREEMENTJoint Filing Agreement • October 31st, 2007 • Efficacy Capital, Ltd. • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13G (including amendments thereto) with regard to the common stock of Repros Therapeutics, Inc., a Delaware corporation, and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings. In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of December 31, 2006.
AGREEMENT REGARDING JOINT FILINGAgreement Regarding Joint Filing • October 10th, 2006 • Efficacy Capital, Ltd. • Pharmaceutical preparations
The undersigned, Efficacy Capital Ltd., Efficacy Biotech Fund, L.P., Efficacy Biotech Fund Ltd., Efficacy Biotech Master Fund Ltd., Jon Faiz Kayyem and Mark Lappe, hereby agree and acknowledge that the information required by the Schedule 13D to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any amendments or supplements thereto shall also be filed on behalf of each of them.
AGREEMENT REGARDING JOINT FILINGAgreement Regarding Joint Filing • November 20th, 2006 • Efficacy Capital, Ltd. • Pharmaceutical preparations
The undersigned, Efficacy Capital Ltd., Efficacy Biotech Fund, L.P., Efficacy Biotech Fund Ltd., Efficacy Biotech Master Fund Ltd., Jon Faiz Kayyem and Mark Lappe, hereby agree and acknowledge that the information required by the Schedule 13D to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any amendments or supplements thereto shall also be filed on behalf of each of them.
